Aleks Engel of Novo Holdings, another asset manager, cites this model as a perennial gripe among fellow investors in antibiotics.

另一名资产经理，Novo Holdings的亚历克斯·恩格尔把这种模式看做是抗生素投资者常年的抱怨。